TITLE

Optimizing antiplatelet therapy in acute coronary syndromes: Balancing efficacy and safety in unstable angina and non-ST-segment elevation myocardial infarction

PUB. DATE
August 2010
SOURCE
American Journal of Health-System Pharmacy;8/1/2010, Vol. 67 Issue 15, pS29
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
A quiz concerning the article "Optimizing antiplatelet therapy in acute coronary syndromes: Balancing efficacy and safety in unstable angina and non-ST-segment elevation myocardial infarction" is presented.
ACCESSION #
52449280

 

Related Articles

  • CATS: High platelet count predicted VTE in patients with cancer.  // Hem/Onc Today;1/25/2010, Vol. 11 Issue 2, p30 

    The article focuses on the Vienna Cancer and Thrombosis Study that found that a high platelet count was associated with a threefold or more increased risk for venous thromboembolism.

  • Platelet activation and turnover in the primary antiphospholipid syndrome. Joseph, J.E.; Donohoe, S.; Harrison, P.; Mackie, I.J.; Machin, S.J. // Lupus;1998, Vol. 7 Issue 5, p333 

    Thromboembolism is a common occurrence in patients with the antiphospholipid syndrome (APS). The mechanism responsible for this phenomenon is unclear; there are several theories. One possibility is that a pathogenic interaction exists between antiphospholipid antibodies and platelets, leading to...

  • Decreased platelet aggregation, increased bleeding time and resistance to thromboembolism in P2Y1-deficient mice. Fabre, Jean-Etienne; Nguyen, MyTrang; Latour, Anne; Keifer, Jayne A.; Audoly, Laurent P.; Coffman, Thomas M.; Koller, Beverly H. // Nature Medicine;Oct99, Vol. 5 Issue 10, p1199 

    Platelet activation is characterized by shape change, induction of fibrinogen receptor expression and release of granular contents, leading to aggregation and plug formation. While this response is essential for hemostasis, it is also important in the pathogenesis of a broad spectrum of...

  • Diabetic Patients Without Vascular Complications Display Enhanced Basal Platelet Activation and Decreased Antioxidant Status. Véricel, Evelyne; Januel, Caroline; Carreras, Martine; Moulin, Philippe; Lagarde, Michel // Diabetes;Apr2004, Vol. 53 Issue 4, p1046 

    Vascular complications are the leading causes of morbidity and mortality in diabetic patients. The contribution of platelets to thromboembolic complications is well documented, but their involvement in the initiation of the atherosclerotic process is of rising interest. Thus, the aim of the...

  • AN ANESTHESIA PROVIDER'S PERSPECTIVE OF HEPARIN-INDUCED THROMBOCYTOPENIA. Woodyard, Daniel Nay // AANA Journal;Apr2005, Vol. 73 Issue 2, p115 

    Heparin-induced thrombocytopenia (HIT) is a pathology manifested as clinically induced destruction of platelets. There are 2 forms of HIT, type l and type II; type II is the more serious. HIT type I is a transient, non-immune-mediated form manifesting with mild thrombocytopenia. Type II is a...

  • Serum Ig E Concentration In Acute Pulmonary Thromboembolism. Erkan, Levent; Talu, Aynur; Findik, Serhat; Talu, Cengiz // Internet Journal of Pulmonary Medicine;2002, Vol. 2 Issue 2, p32 

    Background : Events mediated by immunoglobulin E (IgE) may be related to platelet activation and aggregation, and serum IgE concentrations may increase in various vascular diseases such as previous myocardial infarction, previous stroke and current large-vessel peripheral arterial disease. There...

  • Heparin-Induced Thrombocytopenia and Paradoxical Thromboembolism: Diagnostic and Therapeutic Dilemmas. Bick, Rodger L. // Clinical & Applied Thrombosis/Hemostasis;Jan1997, Vol. 3 Issue 1, p63 

    Highlights important points of a study on therapy for patients with heparin-induced thrombocytopenia (HIT) and paradoxical thromboembolism. Types of HIT; Physiological mechanism for HIT; Laboratory diagnostic tools for HIT; Therapeutic modalities for HIT.

  • Antiplatelet treatment for thromboprophylaxis: a step forward or backwards? Cohen, Alexander T.; Skinner, John A.; Kakkar, Vijay V. // BMJ: British Medical Journal (International Edition);11/5/94, Vol. 309 Issue 6963, p1213 

    Argues the adoption of antiplatelet treatment for thromboprophylaxis. Existence of effective alternative treatments of thromboembolism; Evidence of the ineffectiveness of the treatment on deep vein thrombosis and of pulmonary embolism; Advantages of the use of the antiplatelet treatment on...

  • Antiplatelet therapy for throboprophylaxis: the need for careful consideration of the evidence from randomised trials. Collins, R.; Baigent, C.; Sandercock, P.; Peto, R. // BMJ: British Medical Journal (International Edition);11/5/94, Vol. 309 Issue 6963, p1215 

    Examines the effectiveness of antiplatelet therapy for thromboprophylaxis. Reduction of the thromboembolism with the therapy and with subcutaneous heparin; Effects of the reduction of pulmonary embolism for people at higher risk; Effects of antiplatelet therapy on surgical bleeding.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics